FBXL3 and nonpapillary renal cell carcinoma: Cox regression analysis in the anti-PD-1 cohort revealed that only FBXL3, FBXO3, and PBRM1 mutation could serve as biomarkers of immunotherapy for patients with ccRCC (Figure 8C).